Clarithromycin is a semisynthetic macrolid antimicrobial drug for treatment of community acquired respiratory infections

1. Страчунский Л.C., Козлов С.И. Макролиды в современной клинической практике. Смоленск: Русич; 1998.

2. Внебольничная пневмония у взрослых: Практические рекомендации по диагностике, лечению и профилактике/ Чучалин А.Г., Синопальников А.И., Яковлев С.В. и др. М.; 2003.

3. Ball P. Therapeutic considerations for the management of respiratory tract infections. The role of new macrolides and fluoroquinolones. Infect, in Med. 1991; 8 (suppl.A): 7-17.

4. Bergeron M .G., Bernier М ., L'Eciyer J. In vitro activity of clarithromycin and its 14-hydroxy metabolite against beta-lactamase positive and negative strains of haemophilus influenzae. In: 1st International conference on the macrolides, azalides and streptogramins. Santa Fe, New Mexico, 1992. 25-26.

5. Georgopoulos A., Sauermann R., Gattringer R. et al. Resistance of S.pneumoniae to macrolides and other antibiotics in Central Europe. In: 42nd ICAAC. San Diego; 2002. 166, abstr. E-1658.

6. Grudinina S.A., Egorov A.M ., Zubkov M .M ., Sidorenko S.V'. Four-year surveillance of antibiotic resistance in Streptococcus pneumoniae in Moscow. ICMAS-KO 6. Bologna; 2002. Abstr. 3.31.

7. Guay D.R., Patterson R., Seipman N., Craft J.C. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Safety 1993; 8 (5): 350-364.

8. Jones R.N., Erwin M .E., Barrett M.S. In vitro activity of clarithromycin and 14-OH clarithromycin alone and in combination against Legionella species. Eur. J. Clin. Microbiol. Infect. Dis. 1990; 9: 846-848.

9. Kees F., Wellenhofer М ., Grobecker H. Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers. Infection 1995; 23: 168-172.

10. Kozlov R.S., Appelbaum P.C., Kosowska K. et al. Comparison of antimicrobial resistance of nasopharyngeal pneumococci from children from day care'centers in European and Asian Russia. In: 43rd ICAAC. Chicago; 2002. 130, abstr. C2-937.

11. Labro M .T. Pharmacology of spiramycin in comparison with other macrolides. Drug Invest. 1993; 6 (suppl.l): 15-28.

12. Neu H.C. The development of macrolides: clarithromycin in perspective. J. Antimicrob. Chemother. 1991; 27 (suppl.A): 1-9.

13. Periti P., Mazzei T. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosages regimen. J. Chemother. 1999; 11 (1): 11-27.

14. Peters D .H ., Clissold S.P. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44 (1): 117-124.

15. Scrock C.G. Clarithromycin vs penicillin in the treatment of streptococcal pharyngitis. J. Fam. Pract. 1992; 35: 622-626.

16. Takeds H., Miura H., Kawahira M . et al. Long-term administration study on TE-031 (A-56268) in treatment oi diffuse panbronchiolitis. Kansenshogaki Zasshi 1989; 63: 71-78.

17. Williams J.D., Sefton A.M . Comparison of macrolide antibiotics. J. Antimicrob. Chemother. 1993; 31 (suppl.C): 11-26.

18. Yutanova N.S., Sidorenko S.V., Yakovlev S .F., Grudinina S.A. Pharmacodynamic of new slowly-released pharmaceutical form of clarithromycin for pneumococcal pneumonia. In: 10th Scientific meeting European society of chemotherapy infectious diseases. Vienna; 2003. Abstr. F5.